文献速递心脏核医学肿瘤 PET/CT

延长高脂高蛋白极低碳水化合物饮食预处理抑制疑似心脏结节病患者FDG-PET/CT检查前心肌18F-FDG摄取

Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis.
PubMed 文献 · Clin Nucl Med · 2017-01-01

该回顾性研究纳入207例活检证实结节病且临床怀疑心脏结节病的患者共215次FDG-PET/CT检查,比较24小时或更短与72小时高脂高蛋白极低碳水化合物饮食预处理对心肌FDG摄取的影响。72小时组不确定率显著低于短程组(P<0.001),提示延长预处理可抑制生理性心肌摄取,可能有助于更敏感准确地诊断活动性心脏结节病。

要点

  • 72小时高脂高蛋白极低碳水化合物饮食组不确定率为3.6%,短程组为41.7%,组间差异P<0.001。
  • 72小时组阴性率86.7%、阳性率9.8%;短程组阴性率50.0%、阳性率8.3%。
  • PET阳性心肌病灶SUVmax范围3.4~12.5,纵隔血池SUVmean范围1.1~3.6。

核心结论

  • 延长72小时高脂高蛋白极低碳水化合物饮食预处理方案成功抑制了生理性心肌FDG摄取,可能使FDG-PET/CT诊断活动性心脏结节病更敏感、更准确。

研究设计与样本

  • 回顾性研究,纳入2014年7月至2015年12月207例活检证实结节病且临床怀疑心脏结节病的患者共215次FDG-PET/CT检查。
  • 第1组为12例患者的12次FDG-PET/CT检查,检查前高脂高蛋白极低碳水化合物饮食预处理24小时或更短。
  • 第2组为203次FDG-PET/CT检查,检查前进行72小时高脂高蛋白极低碳水化合物饮食预处理;排除不依从者及合并癌症者。
  • 心脏FDG摄取分为无摄取及基底部环形弥漫摄取(心脏结节病阴性)、局灶性摄取(阳性)和弥漫性摄取(不确定)。
  • 最终诊断由医师结合包括心脏MRI和超声心动图在内的所有临床信息共识确定。

主要发现

  • 第1组12次检查中,心脏结节病阳性1次(1/12,8.3%)、不确定5次(5/12,41.7%)、阴性6次(6/12,50.0%)。
  • 第2组排除10例后余185例患者共193次FDG-PET/CT检查(重复8次),其中阳性19次(19/193,9.8%)、不确定7次(7/193,3.6%)、阴性167次(167/193,86.7%)。
  • 第2组不确定率显著低于第1组(P<0.001)。
  • PET阳性心肌病灶SUVmax范围为3.4至12.5,纵隔血池SUVmean范围为1.1至3.6。

关键数值与推荐

  • 心脏FDG摄取判读标准:无摄取和基底部环形弥漫摄取为心脏结节病阴性,局灶性摄取为阳性,弥漫性摄取为不确定。
  • 第1组阳性率8.3%、不确定率41.7%、阴性率50.0%;第2组阳性率9.8%、不确定率3.6%、阴性率86.7%。
  • 第2组不确定率显著低于第1组(P<0.001)。

临床怎么用

  • 原文结论认为延长72小时高脂高蛋白极低碳水化合物饮食预处理方案可能使FDG-PET/CT诊断活动性心脏结节病更敏感、更准确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A major obstacle in using FDG-PET/CT to diagnose cardiac sarcoidosis (CS) is the unpredictable physiological myocardial FDG uptake. We hypothesized that a prolonged 72-hour pretest high-fat, high-protein, and very-low-carbohydrate (HFHPVLC) diet preparation could suppress physiologic myocardial uptake of FDG and thus help to identify active CS. METHODS: This retrospective study included 215 FDG-PET/CT tests from 207 patients with biopsy-proven sarcoidosis and clinical suspicion for CS between July 2014 and December 2015. The patients were classified into 2 groups. Group 1 included 12 FDG-PET/CT scans from 12 patients who had 24-hour or less pretest HFHPVLC diet preparation. Group 2 included 203 FDG-PET/CT scans with 72-hour HFHPVLC diet before FDG-PET/CT. Nonadherent patients and patients with cancer were excluded. Cardiac FDG uptake was classified as: "none" and "ringlike diffuse at base" (negative for CS), "focal" (positive for CS), and "diffuse" (indeterminate for CS). FDG uptake in myocardial lesions was measured as SUVmax and compared with SUVmean of mediastinal blood pool. Final diagnoses were made with consensus among physicians in view of all available clinical information including cardiac MRI and echocardiogram results. RESULTS: In group 1, there were 1 (1/12, 8.3%) positive, 5 (5/12, 41.7%) indeterminate, and 6 (6/12, 50.0%) negative for CS. In group 2, 10 patients were excluded (6 patients because of noncompliance with diet, 2 patients with concurrent diagnosis of cancers, 2 patients because of insulin and steroid use within 4 hours before PET/CT); the remaining 185 patients had 193 FDG PET/CT tests (8 repeats), of which there were 19 (19/193, 9.8%) positive, 7 indeterminate (7/193, 3.6%), and 167 (167/193, 86.7.%) negative for CS. The SUVmax of PET-positive myocardial lesions ranges from 3.4 to 12.5, whereas mediastinal blood pool SUVmean ranges from 1.1 to 3.6. The indeterminate rate was significantly lower in group 2 compared with group 1 (P < 0.001). CONCLUSIONS: The prolonged 72-hour HFHPVLC diet preparation protocol successfully suppressed physiological myocardial FDG uptake and may permit a more sensitive and accurate method of diagnosing active CS using FDG PET/CT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lu Y, Grant C, Xie K, et al. Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis. Clin Nucl Med. 2017. PMID: 27922863. doi:10.1097/RLU.0000000000001465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。